Recite me link

Q1. How many patients were treated (for any condition) in the latest 6-month period with the following drugs:
a. Juluca (rilpivirine/dolutegravir)
b. Dovato (lamivudine/dolutegravir)
c. Triumeq (abacavir/lamivudine/dolutegravir)
d. Tivicay (dolutegravir)
e. Isentress (raltegravir)
f. Biktarvy (TAF/emtricitabine/bictegravir)
g. Genvoya (TAF/emtricitabine/elvitegravir/cobisistat)
h. Symtuza (TAF/emtricitabine/darunavir/cobisistat)
i. Odefsey (TAF/emtricitabine/rilpivirine)
j. Descovy (TAF/emtricitabine)
k. Truvada or generic TDF/emtricitabine
Q2. How many patients received any antiretroviral (ART) therapy for HIV treatment (excluding pre-exposure prophylaxis):
a. for the latest 6-month period
b. for the 6 months from July-December 2019
Q3. How many patients were treated in the latest 6-months period with Truvada or generic TDF/emtricitabine for?
a. HIV treatment
b. Pre-exposure prophylaxis (PrEP)
Q4. How many packs of Truvada or generic TDF/emtricitabine were dispensed in latest 6-month period for?
a. HIV treatment
b. Pre-exposure prophylaxis (PrEP)

Download response Antiretroviral therapies. 140521